ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
- Tuesday, November 12, 2019, 7:12
- PR Newswire
- Add a comment
INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week placebo-controlled Phase 3 study evaluating the safety and efficacy of…
About the Author
admin has written 21793 stories on this site.